In this episode of the Claims Theory Podcast, Lindsay sits down with Chad Zoretic of VMG Health to break down what is really happening in ambulatory surgery center M&A right now.
Are valuations stabilizing or compressing? What EBITDA multiples are buers actually paying in 2026? Is this a buyer's market or a seller's market? And how much does revenue cycle performance really impact deal value?
Chad works at the intersection of ASCs, private equity, and high-level financial strategy. Together, the unpack:
Current ASC deal flow trendsEBITDA multiples for single-site vs. platform dealsWhat buyers are prioritizing right nowFinancial red flags that kill valuationHow disciplined operations drive premium exitsWhere the ASC market is headed over the next 3-5 yearsIf you own, operate, invest in, or advise ASCs, this is a must-listen.
Because in 2026, preparation is not optional.
Discipline drives valuation.